Evidence map›Paper›PMID 39898301›Full record

ArticleEpilepsy & behavior reports2025

The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study.

Christin Eltze, Shaikha Alshehhi, Aisha Al Ghfeli, Kishan Vyas, Seeta Saravanai-Prabu, Gaelle Gusto, Artak Khachatryan, Marta Martinez, Archana Desurkar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christin EltzeGreat Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK.
Shaikha AlshehhiGreat Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK.
Aisha Al GhfeliGreat Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK.
Kishan VyasJazz Pharmaceuticals UK Ltd., 1 Cavendish Place, London W1G 0QF, UK.
Seeta Saravanai-PrabuJazz Pharmaceuticals UK Ltd., 1 Cavendish Place, London W1G 0QF, UK.
Gaelle GustoCertara, 71 Rue de Miromesnil, Paris 75008, France.
Artak KhachatryanCertara, Acero Level 2, 1 Concourse Way, Sheffield SN1 2BJ, UK.
Marta MartinezCertara, Av Gran Via, 46, 48011 Bilbao, Bizkaia, Spain.
Archana DesurkarSheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate clinical outcomes from the UK Early Access Program in patients aged 2-17 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) treated with plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution). Methods: Retrospective chart review of data collected from baseline (1 month before CBD treatment initiation) until 12 months' treatment, CBD discontinuation, death, or loss to follow up. Results: At baseline, all 26 patients enrolled (LGS, Conclusion: Results demonstrate a reduction in motor seizures and a safety profile consistent with previous studies.

Indexed as

CannabidiolClinical practiceDravet syndromeEarly Access ProgramLennox-Gastaut syndromeSeizure

Identifiers

PMID39898301
PMCPMC11786083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.